The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | RIC vs MAC in MRD-positive & MRD-negative patients with AML
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on the use of reduced-intensity conditioning (RIC) and myeloablative conditioning (MAC) in patients with acute myeloid leukemia (AML) who are measurable residual disease (MRD)-positive or MRD-negative. Whilst studies have suggested that MRD-positive patients should be treated with MAC, it is necessary to conduct a prospective study to determine the best conditioning regimen for MRD-negative patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
